
Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound for modulating c-Kit activity according to Formula I,



I

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

ring A is a five- to fourteen-membered heteroaryl;

each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

two adjacent of R¹, together with the annular atoms to which they are attached, can form a five-to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

 L^1 is selected from a single bond, an optionally substituted C_{1-2} alkylene, -O-, -CH₂O-, -N(R⁷)-, -C(=O)N(R⁷)-, -SO₂N(R⁷)-, -CH₂N(R⁷)-, and -S(O)₀₋₂-;

ring B is a five- to ten-membered aryl or a five- to ten-membered heterocyclyl;

each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}

- 6alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁-6alkyl;
- two adjacent of R², together with the annular atoms to which they are attached, can form a five-to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁵;
- $L^2 \text{ is a selected from } C_4 \text{alkylene, } C_4 \text{alkylidene, } C_4 \text{alkylidyne, } -X(CH_2)_2 \text{O-, } -X(CH_2)_2 \text{N}(R^7) \text{-, } -XCH_2 \text{SO}_2 \text{N}(R^7) \text{-, } -XN(R^7) \text{C}(=0) \text{N}(R^7) \text{-, } -XCH_2 \text{C}(=0) \text{N}(R^7) \text{-, } -(CH_2)_3 \text{X-, } -XN(R^7) \text{SO}_2 \text{N}(R^7) \text{-, } -XCH_2 \text{N}(R^7) \text{SO}_2 \text{-, } -CH_2 \text{X}(CH_2)_2 \text{-, } -CH=CHC(=0) \text{N}(R^7) \text{-, } -CH=CHSO_2 \text{N}(R^7) \text{-, } -XCH_2 \text{N}(R^7) \text{C}(=0) \text{-, } -M \text{-M-, } -CH_2 \text{N}(R^7) \text{C}(=0) \text{O-, } \text{ and } -CH_2 \text{OC}(=0) \text{N}(R^7) \text{-; } \text{wherein } \text{X is selected from } -CH_2 \text{-, } -O \text{-, } -N(R^7) \text{-, } -C(=0) \text{-, } \text{and } -S(O)_{0 \text{-} 2} \text{-; } \text{M is selected from } -C(=O) \text{N}(R^7) \text{- } \text{and } -SO_2 \text{N}(R^7) \text{-; } \text{and any } \text{C-H of } L^2 \text{ is optionally } \text{C-R}^{20};$
- ring C is either a five- to ten-membered aryl or a five- to ten-membered heteroaryl;
- each R^3 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide;
- two adjacent of R³, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R²⁵;
- R^4 is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted

- five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkenyl, and optionally substituted C_{1-6} alkynyl;
- R^7 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, - $SO_2N(R^4)R^4$, - CO_2R^4 , - $C(=O)N(R^4)R^4$, - $C(=NR^5)N(R^4)R^4$, - $C(=NR^5)R^4$, - $C(=O)R^4$, optionally substituted alkoxy, optionally substituted aryl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and
- each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

provided:

- 1) when both ring B and ring C are phenyl:
 - a) and the compound comprises ring B-CH₂N(H)C(=O)N(H)-ring C, then L¹ must be a single bond; R³ can not comprise a group of the formula -O(CH₂)₂₋₄-N-piperazine that is *ortho* to L²; and ring A cannot be a 5-methyl-[1,2,4]-oxadiazol-3-yl radical, a 4H-[1,2,4]-oxadiazol-5-one-3-yl radical, nor a 4'-[2,2';6',2"]terpyridinyl radical;
 - b) and L¹ is single bond, then L² cannot comprise -N(H)C(=O)C(=O)N(H)- nor -N(H)C(=Q)C(H)CNC(=O)- (where Q is S or O);
 - c) and L¹ is other than single bond, then A cannot be quinolin-2-yl-L¹, quinolin-3-yl-L¹, or quinolin-4-yl-L¹;
- 2) when ring A is a fused aryl system, then L¹ must be a single bond;

- 3) when ring B is phenyl, ring C is a C_{6-16} carbocyclic, L^1 is a single bond, and the compound comprises -ring B-OCH₂C(=O)N(H)- then ring A cannot be a 2,5dimethyl-1H-pyrrole-1-yl radical;
- 4) ring A cannot be a pyrimidin-2-yl radical when L¹ is -N(H)- and ring B is phenyl;
- 5) when the compound comprises the formula,

$$A$$
 B
 C

one

where V is =C(H)- or =N-, and there is a nitrogen of L^2 bound directly to ring B, then A can not comprise a [1,2,4]-oxadiazol-3-yl radical; and


6) the compound is not yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, trimethylphenyl)acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide,

N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-N-[4-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1- $N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1 N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1 N-(2,6-dimethylphenyl)-2-{[3-(1H-tetrazol-1 2-\{[3-(1H-tetrazol-1-yl)phenyl]oxy\}-N-(2,4,6 N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-$ N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1- $N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-$ N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1- $N-[2-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1 N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-$ N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-

yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl]acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-(trifluoromethyl)phenyl]acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino]benzoate, 4-[({[3-(1H-tetrazol-1ethyl yl)phenyl]oxy}acetyl)amino]benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl] oxy}acetyl)amino]benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1Htetrazol-1-yl)phenyl]oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acet-amide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide.

- 2. (original) The compound according to claim 1, wherein L¹ is a single bond.
- 3. (original) The compound according to claim 2, wherein ring A contains between one and four annular nitrogens.
- 4. (original) The compound according to claim 3, wherein ring A is selected from the following:

$(R^1)_{0-4}$	$(R^1)_{0-3}$	$(R^1)_{0-3}$
$Z = \frac{1}{ J }$ $N = \sqrt{R^{1}}$ $(R^{1})_{0-1}$	$Z \longrightarrow \{ N^{-1} \}_{N^{-1} \setminus N^{-1}} $ $(R^{1})_{0-2}$	$N - Z$ $/ N$ $(R^1)_{0-1}$



wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, - $S(O)_{0-2}$ -, and - $N(R^7)$ -.

- 5. (original) The compound according to claim 4, wherein ring B is phenylene or pyridylene.
- 6. (original) The compound according to claim 5, wherein the annular atoms of ring B to which L^1 and L^2 are attached are not contiguous.
- 7. (original) The compound according to claim 6, wherein L^2 is selected from $-X(CH_2)_2O_7$, $-X(CH_2)_2N(R^7)_7$, $-CH_2XC(=O)N(R^7)_7$, $-XCH_2SO_2N(R^7)_7$, $-XN(R^7)C(=O)N(R^7)_7$ and $-XCH_2C(=O)N(R^7)_7$; wherein X is selected from $-CH_2$ -, $-O_7$, $-S(O)_{0-2}$ and $-N(R^7)_7$; and any C-H of L^2 is optionally $C-R^{20}$.
- 8. (original) The compound according to claim 7, wherein L^2 is selected from -N(H)N(H)C(=O)N(H)-, $-CH_2N(H)C(=O)N(H)$ -, $-CH_2OC(=O)N(H)$ -, and $-XCH_2C(=O)N(H)$ -; wherein X is selected from -O-, $-S(O)_{0-2}$ -, and $-N(R^7)$ -; and any C-H of L^2 is optionally $C-R^{20}$.
- 9. (original) The compound according to claim 8, wherein ring A is selected from the following:

$(R^1)_{0-4}$	$(R^1)_{0-3}$	$(R^1)_{0-3}$
$Z = \frac{1}{1}$ $N = \frac{1}{1}$ $(R^1)_{0-1}$	$Z = \frac{1}{1}$ $N = \frac{1}{N}$ $(R^1)_{0-2}$	N - Z $N - Z$ $N -$
R^{1}) ₀₋₁	$Z \longrightarrow \{ 1 \} $ $N - \{ -N \} $ $(R^1)_{0-1}$	$Z - N$ $N - \frac{11}{11}$ $(R^1)_{0-1}$
(R ¹) ₀₋₄ Y	$(R^1)_{0-5}$ Z Z	$(R^1)_{0-5}$ Y Z Z
$(R^1)_{0-6}$ Y Y	$(R^1)_{0-6} \underbrace{Y}_{Z} \underbrace{Y}_{Y}$	$(R^1)_{0-6} \xrightarrow{Y} \xrightarrow{Y}$

wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and $-N(R^7)$ -.

- 10. (original) The compound according to claim 9, wherein ring C is phenyl or pyridyl.
- 11. (original) The compound according to claim 10, wherein there exists at least one of R³ that is halogen.
- 12. (original) The compound according to claim 10, wherein there exists at least one of R³ that is trihalomethyl.
- 13. (original) The compound according to claim 10, wherein there exists at least one of R³ that is trifluoromethyl.
- 14. (original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical meta- to L^2 .

- 15. (original) The compound according to claim 10, wherein each of R^3 is independently selected from -H, halogen, trihalomethyl, $-OR^4$, $-CO_2R^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
- 16. (original) A compound for modulating c-Kit activity according to Formula II,

II

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

W is selected from the following:

		· · · · · · · · · · · · · · · · · · ·
$(R^{27})_{0-4}$	$(R^{27})_{0-3}$	$(R^{27})_{0-3}$
$Z = \frac{1}{N} $ $(R^{27})_{0-1}$	$Z = \frac{1}{11}$ $N = \frac{1}{N}$ $(R^{27})_{0-2}$	N - Z $N - Z$ $N -$
R^{27}) ₀₋₁		$Z - N$ $N - \frac{1}{1}$ $(R^{27})_{0-1}$
(R ²⁷) ₀₋₄ Y—Y Y=Y	$(R^{27})_{0-5}$ Y Z Y Z Y Z	$(R^{27})_{0-5} \xrightarrow{Y} \xrightarrow{Y} \xrightarrow{Y}$
$(R^{27})_{0-6} \xrightarrow{Y} \xrightarrow{Y} \xrightarrow{Y}$	$(R^{27})_{0-6} \underbrace{Y}_{Z} \underbrace{Y}_{Y}$	$(R^{27})_{0-6} \xrightarrow{Y} Y \xrightarrow{Y} Y$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -N(R⁵⁵)R⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -CO₂R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl C_{1-6} alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O)₀₋₂-, and -N(\mathbb{R}^7)-

E and G are each independently selected from -O-, -S(O)₀₋₂-, -C(R³¹)R³²-, and -N(R³³)-;

 J_1 and J_2 are each independently = C(H)- or = N-;

- each of R^{26} and R^{30} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R²⁶ or two adjacent of R³⁰, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R³⁵;
- R^{31} and R^{32} are each independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R^{40}) R^{40} , -S(O)₀₋₂ R^{40} , -SO₂N(R^{40}) R^{40} , -CO₂ R^{40} , -C(=O)N(R^{40}) R^{40} , -C(=NR⁵⁰)N(R^{40}) R^{40} , -C(=NR⁵⁰) R^{40} , -N(R^{40})SO₂ R^{40} , -N(R^{40})C(O)R⁴⁰, -NCO₂ R^{40} , -C(=O) R^{40} , optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted

- aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C₁₋₆alkynyl, and optionally substituted C₁₋₆alkynyl;
- R^{55} is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and
- two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.
- 17. (original) The compound according to claim 16, wherein the annular carbons of ring B to which W and E are attached are not contiguous.
- 18. (original) The compound according to claim 17, wherein R^{30} is selected from -H, halogen, trihalomethyl, $-OR^{40}$, $-N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl.
- 19. (original) The compound according to claim 18, wherein there exists at least one of R^{30} that is trihalomethyl.

- 20. (original) The compound according to claim 18, wherein there exists at least one of R^{30} that is trifluoromethyl.
- 21. (original) The compound according to claim 18, according to formula III.

$$(R^{26})_{0-4}$$
 $(R^{30})_{0-5}$
 $(R^{30})_{0-5}$

22. (original) The compound according to claim 21, wherein W is selected from the following:

$(R^{27})_{0-4}$	$(R^{27})_{0-3}$	$(R^{27})_{0-3}$
$Z = \frac{1}{N}$ $N = \frac{1}{N}$ $(R^{27})_{0-1}$	$Z = \frac{1}{11}$ $N = \frac{1}{N}$ $(R^{27})_{0-2}$	N - Z $N - Z$ $N -$
$(R^{27})_{0-1}$		Z N N ") (R ²⁷) ₀₋₁
(R ²⁷) ₀₋₄	$(R^{27})_{0-5} \underset{Z}{\overset{Y}{\longrightarrow}} Z$	$(R^{27})_{0-5}$
$(R^{27})_{0-6}$	$(R^{27})_{0-6} \xrightarrow{Y}$	$(R^{27})_{0-6} \xrightarrow{Y} \qquad \qquad Y \qquad $

and R²⁷ is defined as above.

- 23. (original) The compound according to claim 22, wherein E is selected from -O-, -S(O) $_{0-2}$ -, and -NH-; and G is -CH $_{2}$ -.
- 24. (original) The compound according to claim 22, wherein E is either -CH₂- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (currently amended) The compound according to either claim 23 or claim 24to claim 23, wherein each of R^3 is independently selected from -H, halogen, trihalomethyl, -OR⁴, -CO₂R⁴, -C(=O)R⁴, and optionally substituted C_{1-6} alkyl.
- 26. (original) The compound according to claim 25, wherein at least one of R^{30} is a trifluoromethyl radical *meta* to -E-G-C(=O)N(H)-.
- 27. (currently amended) The compound according to either claim 1 or claim 16to claim 1, selected from Table 3:

Table 3

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H_3C O
2	N-phenyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
3	N-(2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N H ₃ C
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N = N $N = N$ $N = N$
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N=N O H F F CI
6	ethyl 2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	CH ₃
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N = N CH ₃ CI

Table 3

Entry	Name	Structure
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=Z-N NH
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	N-N CI
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N P CI
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N CH ₃
12	N-(4-morpholin-4-ylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	HZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N F F F F F F F F F F F F F F F F F
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CH ₃ H F F F CI
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH ₃ O N F F

Table 3

Entry	Name	Structure
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH_3 H F F F CI
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N O O CH ₃
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
21	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2,5-dioxopyrrolidin-1- yl)phenyl]oxy}acetamide	ON CI FFF
22	(2E)-N-[4-chloro-3- (trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]prop-2-enamide	N=N O H F F CI

Table 3

Entry	Name	Structure
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N.
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C CI FF
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	$CI \longrightarrow CI \longrightarrow K$ $N = N$ $CI \longrightarrow K$ $K = K$
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	N, N S N F F
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N N F F

Table 3

Entry	Name	Structure
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CI FF NH NH N
29	methyl 1-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-1,2,3-triazole-4- carboxylate	H ₃ C, O O O O O O O O O O O O O O O O O O O
30	1,1-dimethylethyl {4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	
31	1,1-dimethylethyl {4-[({[4-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	NN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N
32	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH CH ₃

Table 3

Entry	Name	Structure
33	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	2. Z 2. Z 2. Z 1. Z 1. Z 1. Z 1. Z 1. Z 1. Z 1. Z 1
34	N-(4-aminophenyl)-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
35	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N = N $N = N$ $N =$
36	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N. CH ₃ N N N N N N N N N N N N N N N N N N N
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N N N N F F

Table 3

Entry	Name	Structure
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH ₃ O N F F
39	N-1,3-benzothiazol-2-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N NH N N N N N N N N N N N N N N N N N
40	N-quinolin-8-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ONN N-N'N
41	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	OHO NHN N
42	N-isoquinolin-5-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ONH N-N'N

Table 3

Entry	Name	Structure
43	N-{3-[(phenylmethyl)oxy]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH NN N
44	N-[5-methyl-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C NH N-N'N
45	N-[2,5-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C _O CH ₃ NH N-N'N
46	N-(6-fluoro-1,3-benzothiazol-2-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	F S H N N N
47	methyl 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzoate	H ₃ C.OCO NH N-N.N.

Table 3

Entry	Name	Structure
48	5-chloro-2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzamide	N.N.N H. CI
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N. N. H. O. CH ₃
50	N-[2-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ON NN
51	N-[3-(aminosulfonyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N N.N.N N.N.N
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ O F F F

Table 3

Entry	Name	Structure
53	N-(4-{[(4- methylphenyl)sulfonyl]amino}phenyl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ O;S;O N N N N N N N N N N N N N N N N N N
54	N-(5-phenyl-1H-pyrazol-3-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H-N N-N N-N
55	N-1,3-benzothiazol-2-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N NH N NH
56	N-quinolin-8-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-pyrrole-1-carboxylate	CI F F F

Table 3

Entry	Name	Structure
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	CI F N H
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N CI F F F
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N.N.N. N.N.N. P.F. F
61	4-chloro-N-(2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl)-3- (trifluoromethyl)aniline	CI F F F
62	N-[4-chloro-3-(trifluoromethyl)phenyl]-N- (2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}ethyl)formamide	N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	CI F F F
64	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-3-ylphenyl)oxy]acetamide	CI FF F
65	(2E)-N-[4-fluoro-3- (trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]prop-2-enamide	N=N N=N
66	N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]propanamide	N N = N F F F F F F F F F F F F F F F F
67	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[6-(1H-tetrazol-1-yl)pyrimidin-4- yl]oxy}acetamide	N N F F CI

Table 3

Entry	Name	Structure
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	CI F F F H_3C CH_3 $N-O$
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	CO FF FF
70	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-2-ylphenyl)oxy]acetamide	CI F N H F
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	NNNN H N H F F
72	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-dibenzo[b,d]furan-4- ylphenyl)oxy]acetamide	F F CI

Table 3

Entry	Name	Structure
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N F F CI
74	N-methyl-N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NNNN CH ₃
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	$\begin{array}{c} & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$
76	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ N=N CI F+F
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N H O F F F

Table 3

Entry	Name	Structure
78	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(pyridin-2- ylamino)phenyl]oxy}acetamide	F F F F
· 79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	FF P P P P P P P P P P P P P P P P P P
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	CI F NH NH
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N F F
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	C F F F P P P P P P P P P P P P P P P P

Table 3

Entry	Name	Structure
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	ON H F F F
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N N N N N N N N N N N N N N N N N N N
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	F F F F F F F F F F F F F F F F F F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	CI F F
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C N=N
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	O N F F F N N = N
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F N N = N
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	FON SEN FER F
92	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzenesulfonamide	

Table 3

Entry	Name	Structure
93	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- N-methyl-3-(1H-tetrazol-1- yl)benzenesulfonamide	N O O O F N N N F F
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	F F F F F F F F F F F F F F F F F F F
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H_3C O N F
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H_3C O N H_3C O N H F F
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	CI F N F

Table 3

Entry	Name	Structure
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ C O H O H F F F N N = N
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N N N N N N N N N N N N N N N N N
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	H. O. H. F. F. F. N.
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(2,3,5,6-tetrafluoro-4-pyrimidin-5-ylphenyl)hydrazinecarboxamide	F H N H F F
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	H, N, N, F, F
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N-N-N-O-N-FFF
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CI FF CH ₃
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C, ON N F F

Table 3

Entry	Name	Structure
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ^O N N N N N N N N N F F
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ^O N N N N N N N N F F
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ₁ ONN
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C. _O N
112	1,1-dimethylethyl 2-{4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-indole-1-carboxylate	CI FF F

Table 3

Entry	Name	Structure
113	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 4-(1H-tetrazol-1-yl)benzenesulfonamide	ON ON THE FEBRUARY OF STREET OF STRE
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	HN N=N H N N N N N N N N N N N N N N N N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F N N = N
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N N O N F F F

Table 3

Entry	Name	Structure
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	H, N, N, F, F, F, N,
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	H.N.H.F.F.
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F

Table 3

Entry	Name	Structure
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	CI N N N H F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	H N N F F
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	H N N F F
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	NH HO, CH ₃

Table 3

Entry	Name	Structure
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N N CH ₃
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	CI O CH ₃
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	CI O'CH ₃
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH ₃ O F F F
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro- 3-(trifluoromethyl)phenyl]carbamate	CH ₃ O CI O N F F

Table 3

Entry	Name	Structure
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N O CH ₃ N O CH ₃
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N O CH ₃
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N CH ₃
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N CH ₃
137	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide	CH ₃ O CI N N N N F F

Table 3

Entry	Name	Structure
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	P P F F F F F F F F F F F F F F F F F F
139	N-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N CI F F F
140	N-{[4-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N
141	N-{[3-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N O CI F F F
142	N-{[4-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N

Table 3

Entry	Name	Structure
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ O F F F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH ₃ O F F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	C F F F NH
146	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (isoquinolin-7-yloxy)acetamide	F F CI
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	H, N, N, H, F,

Table 3

Entry	Name	Structure
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	N N N N F F
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N CI P F F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N CI P F F
151	methyl 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2-carboxylate	CH ₃ O O O O O O O O O O O O O O O O O O O
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N N F F

Table 3

Entry	Name	Structure
153	N-{[3-(2-amino-5-methylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CH ₃ NH ₂ NH ₂ CI F F F
154	methyl 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2-carboxylate	H ₃ C ₁ O ₁ O ₁ O ₁ O ₂ O ₃ O ₄ O ₄ O ₅ O ₄ O ₅ O ₄ O ₅ O ₄ O ₅ O ₅ O ₅ O ₆
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	$N = N$ $N = N$ $O = N$ $O = CH_3$
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3- (1H-tetrazol-1-yl)phenyl]methyl}urea	N = N $N = N$ $O = N$ $O = N$ $O = N$ $O = N$
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
158	N-{[3-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH2 O CI F F
159	N-{[4-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N NH_2 CI F F F
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N N N N N N H H F
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CI F F
162	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(pyrimidin-2- yloxy)phenyl]methyl}urea	N N N F F F

Table 3

Entry	Name	Structure
163	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzamide	N N N N N N F F
164	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[2-(dimethylamino)ethyl]pyrazine-2-carboxamide	F F CI HN O HN O HN O
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N N N N N N H F F
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N CI F F F F

Table 3

Entry	Name	Structure
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	N O CH ₃
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N
170	N-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	F N NH ₂ CI CF ₃
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N N N N N N N F F
172	N-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N N CF ₃

Table 3

Entry	Name	Structure
173	N-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	NH ₂ NH ₂ F
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C N N F F
175	[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F O N F F F F
176	[3-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F

Table 3

Entry	Name	Structure
178	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(hydroxymethyl)pyridin-3- yl]phenyl}methyl)urea	HO N CI N N CF ₃
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H_3C N N N N CF_3
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	CN N CF ₃
181	1,1-dimethylethyl (3S)-3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	F F CI HN N N N N N N N N N N N N N N N N N N
182	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	HN P CI HN O HN O

Table 3

Entry	Name	Structure
183	1,1-dimethylethyl (3S)-3-({[3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate	F CI NH O NH NN NH
184	3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	F F CI NH NH O NH NH NH NN N
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN CI F F
186	N-{[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	NH ₂ NH ₂ PF
187	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N-N-N-O-N-FFF

Table 3

Entry	Name	Structure
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CI P N N F F
189	[3-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H_2N O O N F F F
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	SH3 N N CF3
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C N
192	[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F N NH ₂

Table 3

Entry	Name	Structure
193	[4-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON PFF F
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N N N N N N N N N N N N N N N N N
196	[4-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N N CH ₃
197	[3-(1H-tetrazol-1-yl)phenyl]methyl 1,3- benzothiazol-2-ylcarbamate	

Table 3

Entry	Name	Structure
198	[3-(1H-tetrazol-1-yl)phenyl]methyl (5-bromopyridin-2-yl)carbamate	N N N Br
199	(3-pyridin-3-ylphenyl)methyl (3,5-dimethylphenyl)carbamate	CH ₃ CH ₃ CH ₃
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃ ON ON CI
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F N N = N
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2-(methyloxy)phenyl]carbamate	CH ₃ ON N N CI

Table 3

Entry	Name	Structure
203	(4-pyrimidin-5-ylphenyl)methyl (3,4-dimethylphenyl)carbamate	O N CH ₃
204	(3-pyridin-3-ylphenyl)methyl (3,4-dimethylphenyl)carbamate	N CH ₃
205	1,1-dimethylethyl 3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	FFF CI HN N N N N N N N N N N N N N N N N N N
206	1,1-dimethylethyl 3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	FFF CI HN O H ₂ N N

Table 3

Entry	Name	Structure
207	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-piperidin-3-ylpyrazine-2-carboxamide	HN HN N N N N N N N N N N N N N N N N N
208	3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-piperidin-3-ylpyrazine-2-carboxamide	FFF CI NH O H ₂ N N
209	1,1-dimethylethyl 4-{[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	CI FF F O NH O NH NH NH NN
210	1,1-dimethylethyl 4-{[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	F F CI N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
211	N-({3-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	H ₂ N N HN O
212	N-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	F F CI N H O H ₂ N N
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N N CF ₃
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF ₃
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N CF ₃

Table 3

Entry	Name	Structure
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF ₃ CI HN N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI N N CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N H CF ₃
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F CI N N CF ₃
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	P N N CF ₃

Table 3

Entry	Name	Structure
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	NNNN ON FFF
222	[3-(1H-tetrazol-1-yl)phenyl]methyl [6- (trifluoromethyl)pyridin-2-yl]carbamate	N.N.N. ONN.N.F.F
223	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- (trifluoromethyl)pyridin-2-yl]carbamate	N N N F F
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} N O CF ₃
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H_3C O O CF_3 CH_3 O

Table 3

Entry	Name	Structure
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CI N CF ₃
227	2,3'-bipyridin-6-ylmethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N O N F F
228	(6-pyrimidin-5-ylpyridin-2-yl)methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N N O N F F
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	CI N N CF ₃
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	N N CF ₃

Table 3

Entry	Name	Structure
231	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate	N N N F F
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CI N N N N N F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HNNN CI HNNN F F

- 28. (currently amended) A pharmaceutical composition comprising the compound according to any one of claims 1 27 claim 1 and a pharmaceutically acceptable carrier.
- 29. (currently amended) A metabolite of the compound or the pharmaceutical composition according to any one of claims 1 _ 28claim 1.
- 30. (currently amended) A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to any of elaims 1—27claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}

(1H-tetrazol-1-yl)phenyl]oxy} N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1acetamide, yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl] oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoate, benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-3-(1H-tetrazol-1-yl)pheny tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide.

- 31. (original) The method according to claim 30, wherein the kinase is c-Kit.
- 32. (original) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- 33. (currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising

administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 1 28claim 1 or a compound, or a pharmaceutical composition comprising said compound, selected from Nnaphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(2,3-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, acetamide, N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl) N-(2-ethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyl-oxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)-phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy} acetyl) amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-3-(1H-tetrazol-1-yl)pheny tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}

acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide.

(currently amended) A method of screening for modulators of c-Kit, the method 34. comprising combining the compound according to any one of claims 1 27 claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(4-chloro-3-methylphenyl)-2-{[3-(1Hacetamide, tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl) acetamide, phenyl] methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoate, benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-3-(1H-tetrazol-1 tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}

acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.

35. (currently amended) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according to claim 1 any one of claims 1 - 27 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{[3-(1Htetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl 4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoate, benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]-3-(1H-tetrazol-1-yl)pheny

tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, to a cell or a plurality of cells.